CPIX vs. ASMB, ONCT, BIOR, GDTC, BFRG, LUMO, SYBX, MEIP, LSTA, and ENLV
Should you be buying Cumberland Pharmaceuticals stock or one of its competitors? The main competitors of Cumberland Pharmaceuticals include Assembly Biosciences (ASMB), Oncternal Therapeutics (ONCT), Biora Therapeutics (BIOR), CytoMed Therapeutics (GDTC), Bullfrog AI (BFRG), Lumos Pharma (LUMO), Synlogic (SYBX), MEI Pharma (MEIP), Lisata Therapeutics (LSTA), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical preparations" industry.
Assembly Biosciences (NASDAQ:ASMB) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk, community ranking and dividends.
19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 4.1% of Assembly Biosciences shares are held by company insiders. Comparatively, 43.3% of Cumberland Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Assembly Biosciences received 54 more outperform votes than Cumberland Pharmaceuticals when rated by MarketBeat users. Likewise, 59.21% of users gave Assembly Biosciences an outperform vote while only 45.17% of users gave Cumberland Pharmaceuticals an outperform vote.
Assembly Biosciences has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500.
Cumberland Pharmaceuticals has higher revenue and earnings than Assembly Biosciences. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.
Assembly Biosciences has a net margin of 0.00% compared to Assembly Biosciences' net margin of -15.87%. Assembly Biosciences' return on equity of 6.84% beat Cumberland Pharmaceuticals' return on equity.
In the previous week, Cumberland Pharmaceuticals had 2 more articles in the media than Assembly Biosciences. MarketBeat recorded 32 mentions for Cumberland Pharmaceuticals and 30 mentions for Assembly Biosciences. Cumberland Pharmaceuticals' average media sentiment score of 0.02 beat Assembly Biosciences' score of -0.15 indicating that Assembly Biosciences is being referred to more favorably in the media.
Summary
Assembly Biosciences beats Cumberland Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Cumberland Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CPIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cumberland Pharmaceuticals Competitors List
Related Companies and Tools
